The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | MiST5: niraparib and dostarlimab in relapsed malignant mesothelioma
Dean Fennell, FRCP, PhD, University of Leicester, Leicester, UK, discusses the Phase IIa MiST5 trial (NCT03654833) evaluating niraparib and dostarlimab in patients with relapsed malignant mesothelioma. The primary endpoint of the study, disease control rate at 12 weeks, was met, demonstrating promising disease control. Manageable toxicity was additionally reported, supporting further investigation into the cellular and molecular correlates for this combination therapy. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – AstraZeneca; Bayer; Boehringer Ingelheim; Boehringer Ingelheim; Bristol Myers Squibb; RS Oncology (Inst)
Consulting or Advisory Role – Bristol-Myers Squibb; RS Oncology
Speakers’ Bureau – BMS; Boehringer Ingelheim
Research Funding – Astex Pharmaceuticals (Inst); Bayer (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); MSD Oncology (Inst); Owkin (Inst); Roche UK (Inst); RS Oncology (Inst)
Travel, Accommodations, Expenses – Bristol-Myers Squibb; Janssen Oncology; RS Oncology
